当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2015年
23期
105-106
,共2页
西罗莫司转换钙调磷酸蛋白酶抑制剂%肾移植术后糖尿病%临床效果
西囉莫司轉換鈣調燐痠蛋白酶抑製劑%腎移植術後糖尿病%臨床效果
서라막사전환개조린산단백매억제제%신이식술후당뇨병%림상효과
Sirolimus conversion of calmodulin phosphoric acid protease inhibitors%Diabetes after renal transplantation%Clinical effect
目的 探讨肾移植术后糖尿病采用西罗莫司转换钙调磷酸蛋白酶抑制剂治疗的临床效果.方法 对40例肾移植术后糖尿病患者临床资料进行回顾性分析,将其均分为治疗组(西罗莫司转换钙调磷酸蛋白酶抑制剂)和对照组(降糖药物)(n=20),通过不同治疗方法,对2组患者临床治疗效果进行对比分析.结果 2组患者治疗前空腹血糖水平差异无统计学意义;治疗后,2组患者空腹血糖均显著低于治疗前(P<0.05),且治疗组患者治疗后空腹血糖显著低于对照组患者(P<0.05);治疗组患者治疗5年后人生存率为85.00%、肾生存率为75.00%,与对照组患者的60.00%和50.00%相比,差异具有统计学意义(P<0.05).结论 肾移植术后糖尿病临床上采用西罗莫司转换钙调磷酸蛋白酶抑制剂治疗临床效果较为理想.
目的 探討腎移植術後糖尿病採用西囉莫司轉換鈣調燐痠蛋白酶抑製劑治療的臨床效果.方法 對40例腎移植術後糖尿病患者臨床資料進行迴顧性分析,將其均分為治療組(西囉莫司轉換鈣調燐痠蛋白酶抑製劑)和對照組(降糖藥物)(n=20),通過不同治療方法,對2組患者臨床治療效果進行對比分析.結果 2組患者治療前空腹血糖水平差異無統計學意義;治療後,2組患者空腹血糖均顯著低于治療前(P<0.05),且治療組患者治療後空腹血糖顯著低于對照組患者(P<0.05);治療組患者治療5年後人生存率為85.00%、腎生存率為75.00%,與對照組患者的60.00%和50.00%相比,差異具有統計學意義(P<0.05).結論 腎移植術後糖尿病臨床上採用西囉莫司轉換鈣調燐痠蛋白酶抑製劑治療臨床效果較為理想.
목적 탐토신이식술후당뇨병채용서라막사전환개조린산단백매억제제치료적림상효과.방법 대40례신이식술후당뇨병환자림상자료진행회고성분석,장기균분위치료조(서라막사전환개조린산단백매억제제)화대조조(강당약물)(n=20),통과불동치료방법,대2조환자림상치료효과진행대비분석.결과 2조환자치료전공복혈당수평차이무통계학의의;치료후,2조환자공복혈당균현저저우치료전(P<0.05),차치료조환자치료후공복혈당현저저우대조조환자(P<0.05);치료조환자치료5년후인생존솔위85.00%、신생존솔위75.00%,여대조조환자적60.00%화50.00%상비,차이구유통계학의의(P<0.05).결론 신이식술후당뇨병림상상채용서라막사전환개조린산단백매억제제치료림상효과교위이상.
Objective To diabetes after kidney transplantation with sirolimus transformation of calmodulin phosphoric acid protease inhibitor treatment the clinical effect of comparative analysis.Methods 40 cases of renal transplantation in patients with diabetes to explore the clinical data,and divided into a treatment group (Sirolimus conversion of calcineurin inhibitors) and the control group(Hypoglycemic drugs) were 20 cases,different treatment methods for the clinical treatment of the two groups were launched to score analysis.Results The two groups of patients before fasting blood glucose levels; after treatment,patients were fasting blood glucose was significantly lower than before treatment and after treatment,patients treated with fasting blood glucose was significantly lower than the control group of patients(P<0.05); treatment group of patients five years later survival rate was 85.00% and kidney survival rate was 75.00% in the control group of patients with 60.00% and 50.00%,compared with a significant difference(P<0.05).Conclusion In the treatment of kidney transplant surgery on clinical diabetes sirolimus conversion calcineurin protease inhibitor therapy clinicaleffect is better.
